JP2014513126A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513126A5 JP2014513126A5 JP2014509386A JP2014509386A JP2014513126A5 JP 2014513126 A5 JP2014513126 A5 JP 2014513126A5 JP 2014509386 A JP2014509386 A JP 2014509386A JP 2014509386 A JP2014509386 A JP 2014509386A JP 2014513126 A5 JP2014513126 A5 JP 2014513126A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cell
- composition according
- activated
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 210000000447 Th1 cell Anatomy 0.000 claims 5
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 108010029697 CD40 Ligand Proteins 0.000 claims 2
- 102100032937 CD40 ligand Human genes 0.000 claims 2
- 108010039471 Fas Ligand Protein Proteins 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000000961 alloantigen Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 230000000050 nutritive effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161482009P | 2011-05-03 | 2011-05-03 | |
| US61/482,009 | 2011-05-03 | ||
| US201161528484P | 2011-08-29 | 2011-08-29 | |
| US61/528,484 | 2011-08-29 | ||
| US201161564551P | 2011-11-29 | 2011-11-29 | |
| US61/564,551 | 2011-11-29 | ||
| US201261582881P | 2012-01-04 | 2012-01-04 | |
| US61/582,881 | 2012-01-04 | ||
| PCT/US2012/036123 WO2012151279A2 (en) | 2011-05-03 | 2012-05-02 | Induction of il-12 using immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017079200A Division JP6615148B2 (ja) | 2011-05-03 | 2017-04-12 | 免疫療法を用いたｉｌ−１２の誘導 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513126A JP2014513126A (ja) | 2014-05-29 |
| JP2014513126A5 true JP2014513126A5 (https=) | 2015-06-25 |
| JP6393186B2 JP6393186B2 (ja) | 2018-09-19 |
Family
ID=47108207
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509386A Active JP6393186B2 (ja) | 2011-05-03 | 2012-05-02 | 免疫療法を用いたｉｌ−１２の誘導 |
| JP2017079200A Active JP6615148B2 (ja) | 2011-05-03 | 2017-04-12 | 免疫療法を用いたｉｌ−１２の誘導 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017079200A Active JP6615148B2 (ja) | 2011-05-03 | 2017-04-12 | 免疫療法を用いたｉｌ−１２の誘導 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9233156B2 (https=) |
| EP (1) | EP2704732B1 (https=) |
| JP (2) | JP6393186B2 (https=) |
| KR (1) | KR102121492B1 (https=) |
| CN (2) | CN109876138A (https=) |
| AU (3) | AU2012250807A1 (https=) |
| BR (1) | BR112013028285A2 (https=) |
| CA (1) | CA2838046C (https=) |
| IL (1) | IL229177B (https=) |
| PH (1) | PH12013502252B1 (https=) |
| SG (2) | SG194753A1 (https=) |
| WO (1) | WO2012151279A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012151279A2 (en) | 2011-05-03 | 2012-11-08 | Michael Har-Noy | Induction of il-12 using immunotherapy |
| JP6723153B2 (ja) | 2013-12-05 | 2020-07-15 | アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー | 生体内の望ましくない軟部組織を切除するシステム |
| JP6202339B2 (ja) * | 2013-12-19 | 2017-09-27 | 国立研究開発法人国立精神・神経医療研究センター | ＧＭ−ＣＳＦ産生Ｔ細胞制御剤、及びＴｈ１／Ｔｈ２免疫バランス調節剤 |
| KR102128856B1 (ko) | 2015-01-30 | 2020-07-02 | 알에프이엠비 홀딩스, 엘엘씨 | 고주파 전기적 막 파괴를 이용하여 생명체의 바람직하지 않은 연조직을 절제하는 시스템 |
| EP3402517B1 (en) * | 2016-01-15 | 2025-08-20 | RFEMB Holdings, LLC | Immunologic treatment of cancer by using a tumor ablation technic together with a combination of a ctla-4 inhibitor, a pd-1 inhibitor and gm-csf |
| JP2020528077A (ja) * | 2017-07-14 | 2020-09-17 | ミンジェン シュー， | Ｍ１優位の免疫応答を誘導するための方法および薬学的組成物 |
| US12605349B2 (en) | 2024-09-05 | 2026-04-21 | Orbus Therapeutics, Inc. | Methods of treating grade 3 astrocytoma |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2439003A1 (fr) | 1978-10-20 | 1980-05-16 | Anvar | Nouvelles pieces d'osteosynthese, leur preparation et leur application |
| US5766920A (en) | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
| AU7873187A (en) | 1986-08-08 | 1988-02-24 | University Of Minnesota | Method of culturing leukocytes |
| PT89121A (pt) | 1987-12-04 | 1989-12-29 | Du Pont | Processo para a preparacao de interleuquina-2 imobilizada e interleuquina-2 contendo uma extensao no terminal-carboxilo com actividade de interleuquina-2 natural |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| JPH0455577A (ja) * | 1990-06-22 | 1992-02-24 | Mitsubishi Electric Corp | 構造物の制振装置 |
| AU5729294A (en) | 1992-11-25 | 1994-06-22 | Tanox Biosystems, Inc. | Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules |
| DE69430315T2 (de) | 1993-08-06 | 2002-11-21 | Epimmune, Inc. | Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl |
| IL107483A0 (en) | 1993-11-03 | 1994-02-27 | Yeda Res & Dev | Bone marrow transplantation |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| JP3926842B2 (ja) | 1995-03-08 | 2007-06-06 | ザ・スクリプス・リサーチ・インステイチユート | 抗原提示系およびｔ−細胞の活性化方法 |
| DE19545257A1 (de) | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
| JPH09255577A (ja) * | 1996-03-27 | 1997-09-30 | Dainippon Ink & Chem Inc | インターリュウキン−１２誘導剤 |
| ATE347588T1 (de) | 1996-05-23 | 2006-12-15 | Scripps Research Inst | Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten |
| CA2274004A1 (en) | 1996-12-03 | 1998-06-11 | Osteobiologics, Inc. | Biodegradable polymeric film |
| WO1998033891A1 (en) | 1997-01-31 | 1998-08-06 | Hemosol Inc. | Method for the production of selected lymphocytes |
| JP4132089B2 (ja) | 1997-05-30 | 2008-08-13 | オステオバイオロジックス，インコーポレイテッド | 繊維強化多孔性生体分解性移植デバイス |
| CA2309206A1 (en) | 1997-11-10 | 1999-05-20 | Arch Development Corporation | Methods for treatment of tumors and tumor cells using ex vivo activated t cells |
| JP2001054563A (ja) | 1999-07-12 | 2001-02-27 | Isotis Bv | 縫合糸 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US20030119185A1 (en) | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| WO2001062092A1 (en) * | 2000-02-25 | 2001-08-30 | Thomas Jefferson University | Formulations and methods for using the same to elicit an immune response |
| US20020127208A1 (en) | 2000-08-31 | 2002-09-12 | Waller Edmund K. | Method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease |
| US6626950B2 (en) | 2001-06-28 | 2003-09-30 | Ethicon, Inc. | Composite scaffold with post anchor for the repair and regeneration of tissue |
| US20040258661A1 (en) | 2001-10-31 | 2004-12-23 | Daniel Fowler | Generation of use of tc1 and tc2 cells |
| US20030134415A1 (en) * | 2001-09-19 | 2003-07-17 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
| AU2002351277A1 (en) | 2001-12-06 | 2003-07-09 | Georgia Tech Research Corporation | Biodegradable, porous structures useful for growing living tissue, and methods of manufacture |
| US20030175272A1 (en) | 2002-03-07 | 2003-09-18 | Medcell Biologics, Inc. | Re-activated T-cells for adoptive immunotherapy |
| DE10230223A1 (de) | 2002-07-04 | 2004-01-22 | Tegenero Ag | Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern |
| CN1399054A (zh) * | 2002-09-03 | 2003-02-26 | 宋有财 | 旋转式的泊车装置 |
| US7402431B2 (en) | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
| US7435592B2 (en) | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| US20110142887A1 (en) | 2009-12-15 | 2011-06-16 | Immunovative Therapies Ltd. | Methods and compositions for liquidation of tumors |
| US7371228B2 (en) | 2003-09-19 | 2008-05-13 | Medtronic Vascular, Inc. | Delivery of therapeutics to treat aneurysms |
| EP2573166B1 (en) | 2004-02-26 | 2016-05-11 | Immunovative Therapies, Ltd. | Methods for preparing T-cells for cell therapy |
| US7592431B2 (en) | 2004-02-26 | 2009-09-22 | Immunovative Therapies, Ltd. | Biodegradable T-cell Activation device |
| US7446099B2 (en) | 2004-02-27 | 2008-11-04 | Nitto Denko Corporation | Compositions and methods for biodegradable polymer-peptide mediated transfection |
| HUE035726T2 (en) * | 2004-03-01 | 2018-05-28 | Immunovative Therapies Ltd | Cell therapy formulation method and composition |
| EP1744794A2 (en) | 2004-03-05 | 2007-01-24 | The Trustees Of Columbia University In The City Of New York | Polymer-ceramic-hydrogel composite scaffold for osteochondral repair |
| US8865224B2 (en) * | 2004-10-14 | 2014-10-21 | Immunovative Therapies Ltd. | Allogeneic cellular immunotherapy for opportunistic infection |
| WO2007120128A1 (en) | 2006-04-13 | 2007-10-25 | Immunovative Therapies, Ltd. | Allogeneic cell therapy for treatment of opportunistic infection |
| US20080112963A1 (en) | 2006-11-13 | 2008-05-15 | Immunovative Therapies, Ltd. | Ablative immunotherapy |
| US7972594B2 (en) | 2006-11-13 | 2011-07-05 | Immunovative Therapies Ltd. | Ablative immunotherapy |
| EP2025746A1 (en) * | 2007-08-16 | 2009-02-18 | Cell Med Research GMBH | Dendritic cells |
| US20120128656A1 (en) * | 2008-05-02 | 2012-05-24 | Immunovative Therapies, Ltd. | Vaccine compositions and methods |
| WO2012151279A2 (en) * | 2011-05-03 | 2012-11-08 | Michael Har-Noy | Induction of il-12 using immunotherapy |
-
2012
- 2012-05-02 WO PCT/US2012/036123 patent/WO2012151279A2/en not_active Ceased
- 2012-05-02 JP JP2014509386A patent/JP6393186B2/ja active Active
- 2012-05-02 PH PH1/2013/502252A patent/PH12013502252B1/en unknown
- 2012-05-02 CN CN201910193492.3A patent/CN109876138A/zh active Pending
- 2012-05-02 CN CN201280021818.0A patent/CN103687602A/zh active Pending
- 2012-05-02 US US13/581,745 patent/US9233156B2/en active Active
- 2012-05-02 CA CA2838046A patent/CA2838046C/en active Active
- 2012-05-02 SG SG2013081302A patent/SG194753A1/en unknown
- 2012-05-02 KR KR1020137032017A patent/KR102121492B1/ko active Active
- 2012-05-02 EP EP12779711.6A patent/EP2704732B1/en active Active
- 2012-05-02 BR BR112013028285A patent/BR112013028285A2/pt not_active Application Discontinuation
- 2012-05-02 SG SG10201901391RA patent/SG10201901391RA/en unknown
- 2012-05-02 AU AU2012250807A patent/AU2012250807A1/en not_active Abandoned
-
2013
- 2013-10-31 IL IL229177A patent/IL229177B/en active IP Right Grant
-
2015
- 2015-12-08 US US14/962,728 patent/US11045541B2/en not_active Expired - Fee Related
-
2017
- 2017-04-12 JP JP2017079200A patent/JP6615148B2/ja active Active
- 2017-06-15 AU AU2017204058A patent/AU2017204058A1/en not_active Abandoned
-
2019
- 2019-07-01 AU AU2019204699A patent/AU2019204699A1/en not_active Abandoned
-
2021
- 2021-05-20 US US17/326,009 patent/US11883490B2/en active Active
-
2024
- 2024-01-17 US US18/415,111 patent/US20240148865A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513126A5 (https=) | ||
| Ni et al. | Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors | |
| Sakuishi et al. | TIM3+ FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer | |
| Ye et al. | The significance of tumor necrosis factor receptor type II in CD8+ regulatory T cells and CD8+ effector T cells | |
| Berg et al. | Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells | |
| Uhlin et al. | Adjunct immunotherapies for tuberculosis | |
| Sabat et al. | Biology of interleukin-10 | |
| Tonn et al. | Treatment of patients with advanced cancer with the natural killer cell line NK-92 | |
| JP2014087372A5 (https=) | ||
| Capitini et al. | Modulating T‐cell homeostasis with IL‐7: preclinical and clinical studies | |
| Leong et al. | Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells | |
| Ben Khelil et al. | Harnessing antitumor CD4+ T cells for cancer immunotherapy | |
| Hailemichael et al. | Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion | |
| JP2012521215A5 (https=) | ||
| MY180750A (en) | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy | |
| Nielsen et al. | Impaired NK cell responses to pertussis and H1N1 influenza vaccine antigens in human cytomegalovirus-infected individuals | |
| JP2018516586A5 (https=) | ||
| JP2017525364A5 (https=) | ||
| CA2642532A1 (en) | Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject | |
| JP2011006491A5 (https=) | ||
| AR057582A1 (es) | Agentes para suprimir la induccion de linfocitos t citotoxicos | |
| JP5118624B2 (ja) | 新規なヒトｔ細胞集団 | |
| JP6525946B2 (ja) | Ｔｈ１特性と細胞溶解性を発現する細胞 | |
| Roberts et al. | TNF blockade maintains an IL-10+ phenotype in human effector CD4+ and CD8+ T cells | |
| Luo et al. | New insights into the stemness of adoptively transferred T cells by γc family cytokines |